Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Noncoverage for Anodyne Therapy?

This article was originally published in The Gray Sheet

Executive Summary

CMS proposes national non-coverage for infrared therapy devices July 26, due to insufficient evidence that the treatment is reasonable and necessary for beneficiaries with peripheral neuropathy, skin ulcers and related conditions. The agency cites poor quality, small sample size and "a significant placebo effect" in the available clinical studies. "Only when basic efficacy has been established can investigators determine through additional studies which populations, if any, might benefit from experimental light therapy," the agency writes. CMS generated the national coverage decision internally, in part due to an FDA warning letter concerning burns from the Anodyne Therapy device (1"The Gray Sheet" Feb. 6, 2006, p. 5). Comments on the proposed decision are due Aug. 25...

You may also be interested in...



In Rare Move, CMS Cites FDA Warning Letter In National Coverage Request

CMS' internally-generated national coverage request for infrared therapy devices uncharacteristically refers to a recent FDA warning letter to manufacturer Anodyne Therapy

Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar

Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.

UK MHRA Updates Assistive Tech And Borderline Regulations

Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT023826

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel